Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer

Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer Curr Breast Cancer Rep (2017) 9:100–110 DOI 10.1007/s12609-017-0248-5 PSYCHO-ONCOLOGY AND SUPPORTIVE CARE (E SHINN AND C FAGUNDES, SECTION EDITORS) Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer 1,2 1,3 Johanna Wassermann & Shoshana M. Rosenberg Published online: 27 April 2017 Springer Science+Business Media New York 2017 . . Abstract Keywords Breast neoplasms Aromatase inhibitors . . Purpose of Review Treatment decisions regarding adjuvant Selectiveestrogenreceptormodulators Decision-making endocrine therapy in breast cancer has become increasingly Medication adherence Patient compliance complex, with non-adherence to treatment one of the most crucial issues. We aimed to review the literature on both as- pects focusing on new finding regarding assessment, determi- Introduction nants, and interventions of decision-making and adherence to adjuvant endocrine therapy. Annually, more than 130,000 women will present with Recent Findings A shared decision-making process is wanted hormone-receptor (HR) + invasive breast cancer in the USA by the patients and can improve patient-related outcomes. [1]. After initial treatment that may involve surgery, radiother- Information needs, preferences, and values regarding adjuvant apy, and chemotherapy, current guidelines recommend that endocrine therapy vary widely. Nearly two-thirds of patients patients take adjuvant endocrine therapy (ET) for at least 5 do not take the adjuvant http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/treatment-decisions-and-adherence-to-adjuvant-endocrine-therapy-in-cWi09CLFI6

References (111)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media New York
Subject
Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-017-0248-5
Publisher site
See Article on Publisher Site

Abstract

Curr Breast Cancer Rep (2017) 9:100–110 DOI 10.1007/s12609-017-0248-5 PSYCHO-ONCOLOGY AND SUPPORTIVE CARE (E SHINN AND C FAGUNDES, SECTION EDITORS) Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer 1,2 1,3 Johanna Wassermann & Shoshana M. Rosenberg Published online: 27 April 2017 Springer Science+Business Media New York 2017 . . Abstract Keywords Breast neoplasms Aromatase inhibitors . . Purpose of Review Treatment decisions regarding adjuvant Selectiveestrogenreceptormodulators Decision-making endocrine therapy in breast cancer has become increasingly Medication adherence Patient compliance complex, with non-adherence to treatment one of the most crucial issues. We aimed to review the literature on both as- pects focusing on new finding regarding assessment, determi- Introduction nants, and interventions of decision-making and adherence to adjuvant endocrine therapy. Annually, more than 130,000 women will present with Recent Findings A shared decision-making process is wanted hormone-receptor (HR) + invasive breast cancer in the USA by the patients and can improve patient-related outcomes. [1]. After initial treatment that may involve surgery, radiother- Information needs, preferences, and values regarding adjuvant apy, and chemotherapy, current guidelines recommend that endocrine therapy vary widely. Nearly two-thirds of patients patients take adjuvant endocrine therapy (ET) for at least 5 do not take the adjuvant

Journal

Current Breast Cancer Reports – Springer Journals

Published: Apr 27, 2017

There are no references for this article.